Financial Data and Key Metrics Changes - For Q4 2021, the company reported revenue of $2.5 million, a significant increase from $1.1 million in Q4 2020, representing a year-over-year growth of approximately 127% [15] - Total operating expenses for Q4 2021 were $15.9 million, compared to $14.2 million in Q4 2020 [15] - The net loss attributable to common stockholders for Q4 2021 was $15.9 million, or $0.07 per share, compared to a net loss of $13.8 million, or $0.13 per share in Q4 2020 [15][16] - The adjusted net loss for Q4 2021 was $15.7 million, or $0.07 per share, compared to an adjusted net loss of $9.7 million, or $0.09 per share in Q4 2020 [16] - As of December 31, 2021, the company had cash and investments of approximately $135.8 million [16] Business Line Data and Key Metrics Changes - The company expanded its installed base by approximately 33% and increased procedure volumes by 44% in 2021 [7][17] - In 2021, over 2,100 procedures were performed, marking the highest annual procedure volume since the inception of the Senhance system [9] - In Q4 2021, over 500 procedures were performed using Senhance, representing a 30% increase compared to Q4 2020 [10] Market Data and Key Metrics Changes - The U.S. market saw a 95% growth in procedure volumes, while the EMEA region grew by 42% and Asia by 18% compared to 2020 [9] - General surgery accounted for 40% of case volumes, with gynecology, urology, bariatric, and colorectal procedures making up the remaining 60% [10] Company Strategy and Development Direction - The company aims to drive increased awareness of the Senhance platform and publish impactful clinical data to support its adoption [17][18] - Key focus areas for 2022 include market development, portfolio expansion, and technological advancements [18][20] - The company plans to add 10 to 12 new system initiations globally in 2022 and continue to invest in surgeon training and medical education [20][21] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing challenges due to COVID-19, including hospital restrictions and staffing shortages, but expressed optimism about continued growth in procedure volumes [6][32] - The company is focused on leveraging clinical data to demonstrate the value of the Senhance system and expects to see growth in foundational sites throughout 2022 [23][29] Other Important Information - The company received 510(k) clearance for expanded capabilities of the Intelligent Surgical Unit and for 5-millimeter articulating instruments, enhancing the system's dexterity [11][12] - The launch of Senhance Connect, a mobile in-OR communication system, has been well-received and is expected to facilitate better collaboration during surgeries [12] Q&A Session Summary Question: How is the last 60 days looking in terms of procedure volume? - Management indicated steady volume growth but noted unpredictability due to COVID-related fluctuations [32] Question: What is the pediatric market opportunity? - Management acknowledged a significant opportunity in pediatrics, particularly in Europe, and plans to file for pediatric indication in the U.S. [33][35] Question: What is the financial impact from Russia's invasion of Ukraine? - Management stated that while there will be an impact, the extent is still undetermined [38] Question: How do you see outright sales versus sale and leaseback strategies evolving? - Management expects a mix of both outright sales and leaseback strategies, with a slight preference for direct sales as hospital budgets recover [40][41] Question: Have supply chain issues improved in 2022? - Management reported ongoing challenges with supply chains, particularly in semiconductors and medical plastics, with no clear improvement yet [43]

Asensus Surgical, Inc. (NYSE:ASXC) Q3 2021 Earnings Conference Call November 3, 2021 4:30 PM ET Company Participants Mark Klausner - Westwicke, Investor Relations Anthony Fernando - President & Chief Executive Officer Shameze Rampertab - Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Thank you for standing by. This is the conference operator. Welcome to the Asensus Third Quarter Financial and Operating Results Conference Call. As a reminder, all partic ...

Asensus Surgical, Inc. (NYSE:ASXC) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Mark Klausner - Westwicke, Investor Relations Anthony Fernando - President & Chief Executive Officer Shameze Rampertab - Chief Financial Officer Conference Call Participants Operator Good afternoon, ladies and gentlemen, and welcome to the Asensus Surgical, Inc. Second Quarter 2021 Conference Call. During the presentation, all participants will be in a listen-only mode. Afterwards, we will cond ...

Asensus Surgical, Inc. (NYSE:ASXC) Q1 2021 Earnings Conference Call May 11, 2021 4:30 PM ET Company Participants Mark Klausner - Westwicke, IR Anthony Fernando - President and CEO Shameze Rampertab - Chief Financial Officer Conference Call Participants RK - H. C. Wainwright Operator Good afternoon, ladies and gentlemen. And welcome to the Asensus Surgical, Inc.’s First Quarter 2021 Conference Call. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session, ...